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Abstract
The personalization of cancer care is rooted in the premise that there are subsets of patients with 
tumors harboring clinically relevant targets for patient-specific treatments. Colorectal cancer 
(CRC) is a disease that has historically been notable for its dearth of biomarkers that are predictive 
of response to targeted therapies. In recent years, BRAFV600E-mutated CRC has emerged as a 
distinct biologic entity, typically refractory to standard chemotherapy regimens approved for the 
treatment of metastatic CRC and associated with a dismal prognosis. Multiple clinical trials sought 
to replicate the successes of targeted therapies seen in BRAFV600E-mutated melanoma without 
success; metastatic BRAFV600E-mutated CRC is clearly a distinct biologic entity. We review a 
number of recent studies demonstrating the evidence of modest responses to combinations of 
BRAF, EGFR, and/or MEK inhibition in patients with metastatic BRAFV600E-mutated CRC; 
however, despite advances, overall survival remains far inferior for these patients compared to 
their BRAF-wild-type counterparts. Development of combination therapies to impede signaling 
through the MAPK pathway through alternate targets remains an area of active investigation. 
Reflecting the rapid evolution of efforts for this small subset of CRC patients, the first-ever Phase 
III study is now underway evaluating the combination of BRAF, EGFR, and MEK inhibition. 
Immunotherapies are also an area of active research, particularly for the subset of patients with 
tumors that are also microsatellite instability (MSI) high. Here, we summarize the current 
landscape and emerging data on the molecular, clinical, and therapeutic aspects of BRAF-mutant 
CRC.
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Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide1 and the fourth most 
common cancer in the USA.2 Globally, there are ~774,000 deaths each year from CRC.3 
BRAF mutations are present in ~10% of CRC cases. Although malignant melanoma is a 
disease more commonly associated with BRAFV600E mutation, CRC is a much more 
prevalent disease and deaths from BRAF-mutant CRC are predicted to exceed those from 
BRAF-mutant melanoma.1
Moreover, the clinical significance, prognosis, and therapeutic targets of a detected BRAF 
mutation in metastatic CRC provide a stark contrast to melanoma; the alteration at codon 
600 is present in ~50% of melanoma cases4 and is associated with response rates of up to 
80% for treatment with single-agent BRAF inhibitors, including vemurafenib,5 dabrafenib,6 
and encorafenib.7 While responses to single-agent BRAF inhibitors in metastatic melanoma 
are not necessarily durable, there is clear biologic activity. By comparison, single-agent 
vemurafenib was found to have a response rate of <5% in metastatic BRAF-mutant CRC.8 
In recent years, BRAF-mutant CRC has emerged as a distinct biologic entity, refractory to 
standard chemotherapy regimens approved for the treatment of metastatic CRC and 
associated with a dismal prognosis. Here, we summarize the current landscape and emerging 
data on the molecular, clinical, and therapeutic aspects of BRAF-mutant CRC.
The molecular landscape
BRAF is a serine/threonine kinase immediately downstream of KRAS in the MAPK 
signaling pathway; thus, mutations in this gene are detected almost exclusively in KRAS-
wild-type CRC. BRAF-mutant CRC typically harbors a valine (V) to glutamic acid (E) 
change at codon 600 (c.1799T>A or p.V600E). This alteration in the BRAF kinase domain 
results in a constitutively active protein.
In addition to CRC and melanoma, the Cancer Genome Atlas identified BRAFV600E 
mutations in non-small-cell lung cancer, thyroid cancer, cholangiocarcinoma, and gliomas in 
addition to some hematologic malignancies.9 In a population-based study of CRC, 
BRAFV600E mutations strongly associated with hypermutated tumors, frequently exhibiting 
a CpG island methylator phenotype (CIMP) and sporadic microsatellite instability (MSI).10 
The Cancer Genome Atlas similarly identified BRAFV600E mutations in 3% of 
nonhypermutated and 47% of hypermutated colon cancers (n=165 and 30, respectively);11 
however, these numbers may reflect selection bias and likely overestimate the proportion of 
BRAF mutations in hypermutated CRC. A study of 218 CRC tumor specimens with 
BRAFV600E identified two distinct subgroups independent of MSI status, PI3K mutation, 
gender, and sidedness.12 One subset of tumors was characterized by high KRAS/
mTOR/AKT/4EBP1/EMT activation, while the other was characterized by cell cycle 
dysregulation. Identification of these two unique subgroups of BRAFV600E mutations may 
explain the non-uniform responses seen to drug therapies including BRAF and MEK 
inhibitors.
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Although there are other non-V600E BRAF mutations in CRC with a different phenotype, 
none have been identified as strongly prognostic.13 A study performing next-generation 
sequencing of CRC from ~10,000 patients identified non-V600E BRAF mutations in 2.2% 
of cases, accounting for 22% of the total BRAF mutations identified.14 In this study, non-
V600E BRAF mutations in CRC were associated with younger age, male gender, lower-
grade tumor, and less right-sided primaries. Additionally, these mutations were associated 
with improved overall survival (OS) compared to patients with either wild-type BRAF or 
BRAFV600E-mutant CRC. A study of 10 patients with BRAF mutations at codons 594 and 
596 also found these unique mutations to be conversely associated with improved prognosis.
15
Unique clinical presentations
In the early days of understanding BRAF mutant CRC, the clinically defining feature of 
BRAFV600E mutation in CRC was its dismal prognosis. We first observed these patients to 
be at risk for clinical deterioration after rapid sequential progression through multiple lines 
of standard chemotherapy. Many patients died while in queue for the first clinical trials 
offering a hope of personalized therapies.
Since then, we have identified multiple other clinicopathologic features often associated 
with the BRAFV600E mutation. Older age, female gender, and White race have been 
associated with increased likelihood of harboring a BRAFV600E mutation.16–18 Over two-
thirds of BRAFV600E tumors originate in the right colon vs the left colon (68 vs 32%); this 
ratio is in contrast to the typical distribution for BRAF-wild-type tumors, which occur more 
frequently in the left colon (35 vs 65%; P<0.001).19 An analysis of sites of metachronous 
metastases found that BRAFV600E tumors are associated with more frequent peritoneal 
metastases (26 vs 14%; P<0.01) and less frequent liver-limited metastatic disease (41 vs 
63%; P<0.01) at the time of diagnosis.20 When observing the entire disease course, 
significantly higher rates of peritoneal metastases (46 vs 24%; P=0.001) and distant lymph 
node metastases (53 vs 38%; P=0.044) and lower rates of lung metastases (35 vs 49%; 
P=0.049) have been reported in BRAFV600E tumors.19
A retrospective study that matched patients with BRAFV600E-mutant tumors to patients with 
BRAF-wild-type tumors based on tumor location found more peritoneal metastases and 
ascites in the BRAFV600E-mutant tumors. However, when limiting this comparison to only 
patients with right-sided primaries, there was no difference in sites of metastasis.21 Notably, 
the increased incidence of peritoneal metastases and ascites represents unique challenges in 
the interpretation of responses using response evaluation criteria in solid tumors (RECIST 
1.1) in the context of clinical trial evaluations.21
The prognostic and predictive values of a BRAFV600E mutation
Following early clinical observations of the unique disease biology and dramatically inferior 
survival of patients with metastatic BRAFV600E-mutant CRC, several subset analyses from 
multiple large clinical trials and retrospective series sought to further characterize features of 
BRAFV600E-mutant CRC. In the MRC COIN trial of a fluoropyrimidine and oxaliplatin with 
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or without cetuximab, the median OS across treatment arms was 20.1 months for patients 
with RAS/BRAF-wild-type tumors vs 8.8 months for patients with tumors harboring 
BRAFV600E mutations.22 Among patients treated with infusional 5-fluorouracil (5-FU), 
leucovorin and irinotecan (FOLFIRI), and bevacizumab in the FIRE-3 study, BRAFV600E-
mutant tumors were found to have a significantly shorter OS vs those with BRAF-wild-type 
tumors (13.7 vs 20.1 months).23 Cancer and Leukemia Group B (CALGB) 80405 was a 
recent study of the chemotherapy backbones infusional 5-FU, leucovorin and oxaliplatin 
(FOLFOX), or FOLFIRI with the addition of either bevacizumab or cetuximab in metastatic 
CRC.24 Among patients receiving chemotherapy plus bevacizumab, a subset analysis 
demonstrated a median OS of 17.4 months in patients with BRAFV600E mutations vs 35.1 
months in BRAF-wild-type patients.25
Outside of the clinical trial setting, a retrospective study of patients at two major academic 
centers showed a decreased median OS in patients with BRAFV600E mutations of 10.4 vs 
34.7 months (P<0.001).19 Additionally, an analysis of patients with metastatic CRC in the 
Nurses’ Health Study and Health Professionals’ Follow-up Study found that among patients 
with microsatellite stable (MSS) tumors, a BRAFV600E mutation was associated with a 
colon cancer-specific mortality hazard ratio (HR) of 1.60 (95% CI =1.12–2.28; P=0.009).26
Because BRAF testing is not routinely performed in nonmetastatic CRC, less is known 
about the prognostic and predictive values of BRAF mutations in this setting; however, 
retrospective studies from adjuvant chemotherapy trials have provided some insight. In a 
retrospective analysis of tumor samples collected from stages II and III CRC patients in the 
adjuvant PETACC-3 study, BRAFV600E mutations were identified in 7.9% of patients,27 
similar to what is seen in metastatic disease. BRAFV600E mutation was associated with 
decreased OS (HR 1.66; 95% CI 1.15–2.40) in both stages II and III patients, with an even 
more pronounced effect in the MSS cohort with BRAFV600E mutations (HR 2.19; 95% CI 
1.43–3.37). A similar analysis of tumor samples from 2720 stage III patients treated on the 
NCCTG N0147 adjuvant study found that BRAFV600E mutation was associated with worse 
5-year disease-free survival (HR 1.43; 95% CI 1.11–1.85).27 In a retrospective study of 364 
stages II and III patients treated in the Netherlands, a BRAFV600E mutation was detected in 
22% of stage II and 19% of stage III patients.27 In a multivariate model, BRAFV600E was 
similarly associated with worse OS (HR 0.45; 95% CI 0.25–0.8) and cancer-specific survival 
(HR 0.47, 95% CI 0.22–0.99). Based on these studies, it is thought that BRAFV600E 
mutation remains associated with poor prognosis in stages II and III CRC; however, we do 
not have data to substantiate whether or not it is predictive of benefit from adjuvant 
chemotherapy.
Because RAS and BRAFV600E mutations are typically mutually exclusive at diagnosis, 
patients with BRAFV600E mutations were naively included in clinical trials of the anti-
epidermal growth factor receptor (EGFR) therapies, cetuximab and panitumumab, which 
recruited patients with KRAS-wild-type tumors. An initial pooled analysis of 70 cases with 
BRAFV600E mutations from the CRYSTAL and OPUS randomized clinical trials found that 
the addition of cetuximab to first-line chemotherapy was possibly associated with a 
nonsignificant trend toward improved progression-free survival (PFS) and OS for 
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BRAFV600E-mutant metastatic CRC, although inferior OS was observed across treatment 
arms in comparison to BRAF-wild-type patients.28
However, a large meta-analysis of 463 BRAFV600E tumors from one Phase II and nine Phase 
III trials of cetuximab or panitumumab did not show a PFS (HR 0.88; 95% CI 0.67–1.14; 
P=0.33) or an OS (HR, 0.91; 95% CI 0.62–1.34; P=0.63) benefit compared to the control 
chemotherapy arms.29 Another meta-analysis of 351 BRAFV600E mutant tumors from eight 
randomized trials (seven with OS data) similarly did not identify an advantage for anti-
EGFR therapy over the control arm for either PFS (HR 0.86; 95% CI 0.61–1.21) or OS (HR 
0.97; 95% CI 0.67–1.41).30 Although the interaction between BRAFV600E status and 
treatment response was not significant (P=0.43) and the authors concluded that the results 
could be due to chance alone,30 the preponderance of data suggests that patients with 
BRAFV600E mutations are unlikely to derive significant benefit from the currently approved 
anti-EGFR regimens. In line with this, current National Comprehensive Cancer Network 
(NCCN) consensus-based guidelines advise that the presence of a BRAFV600 mutation 
confers a very low likelihood of response to anti-EGFR therapy.31
Revisiting a role for cytotoxic chemotherapy
Secondary analyses of BRAFV600E-mutant subsets from multiple randomized clinical trials 
demonstrating a lack of therapeutic benefit and bleak prognosis with conventional cytotoxic 
chemotherapy doublets32 subsequently spurred attempts at identifying alternative treatment 
options for patients with metastatic BRAFV600E mutant CRC. Given the aggressive nature of 
BRAFV600E disease, clinicians are often faced with the challenge of achieving initial disease 
control in patients at risk for rapid clinical deterioration.33
The TRIBE study evaluated FOLFIRI plus bevacizumab vs infusional 5-FU, leucovorin, and 
oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab.34 Of the 508 patients in this 
study, 28 patients with BRAFV600E mutations were enrolled, of whom 12 patients were 
assigned to the FOLFIRI arm and 16 patients were assigned to the FOLFOXIRI arm. Across 
both arms, the median OS in the RAS-and BRAF-wild-type patients was 37.1 vs 13.4 
months in the small subset of patients with tumors harboring BRAFV600E mutations (HR 
2.79; 95% CI 1.75–4.46; P<0.0001).35 Although the number of patients with BRAFV600E 
mutations in this study was small, the median OS of patients treated with FOLFOXIRI plus 
bevacizumab in TRIBE was 19.0 months compared to 10.7 months in the FOLFIRI plus 
bevacizumab arm (HR 0.54; 95% CI 0.24–1.20).35 An overall response was reported in 56% 
of patients with a BRAFV600E mutation receiving FOLFOXIRI plus bevacizumab vs 42% of 
patients receiving FOLFIRI plus bevacizumab (odds ratio [OR] 1.82, 95% CI 0.91–2.62). 
There was no significant association between treatment effect and BRAF mutation status 
either for OS (P-value =0.52) or for PFS (P-value =0.68),35 suggesting that patients with 
BRAFV600E mutations derived equivalent benefit from FOLFOXIRI over FOLFIRI as their 
BRAF-wild-type counterparts. In the CHARTA Phase II study, in patients with BRAFV600E 
mutations, the median PFS was 10.1 months among patients who received FOLFOXIRI plus 
bevacizumab vs 7.8 months in patients who received FOLFIRI plus bevacizumab (HR 0.72, 
P=0.61).36 Acknowledging the limitations of the small sample size in both of these studies 
and the lack of statistical significance of the trend toward benefit, FOLFOXIRI plus 
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bevacizumab is an option for patients with known metastatic BRAFV600E CRC with well-
preserved performance status for whom early disease control is urgent and imperative. 
Additionally, based on data from Loupakis et al17 showing that female patients with right-
sided primary tumors with mucinous histology have an 81% chance of having a BRAFV600E 
mutation, we consider upfront triplet therapy in patients who meet some of these criteria, 
while molecular analyses are pending.
Although BRAF mutation status was not assessed at the time of the clinical trials that led to 
the approval of bevacizumab in metastatic CRC, it is generally thought that BRAFV600E 
does not preclude response to bevacizumab. As noted earlier in the TRIBE study, significant 
response has been seen with triplet chemotherapy in combination with bevacizumab.34 
Additionally, a subgroup analysis of BRAFV600E-mutated tumors from CAIRO3 showed a 
preserved benefit from bevacizumab containing maintenance therapy compared to no 
maintenance as compared to patients with wild-type tumors.37 However, bevacizumab is 
highly unlikely to overcome the negative prognostic effect of a BRAFV600E mutation; a 
retrospective study of patients treated with FOLFOX plus bevacizumab found the overall 
response rate in patients with a BRAFV600E mutation to be only 18.4%.38
Developing a personalized approach
Since BRAFV600E CRC emerged as a distinct entity, multiple clinical trials have sought to 
replicate the successes of targeted therapies seen in melanoma (Table 1). The two BRAF 
inhibitors, vemurafenib and dabrafenib, revolutionized the treatment of BRAFV600E 
metastatic melanoma and have been shown to be active in BRAFV600E-mutated non-small-
cell lung cancer, anaplastic thyroid cancer, cholangiocarcinoma, Erdheim– Chester disease, 
and Langerhans cell histiocytosis.39 Additionally, single-agent vemurafenib was shown to 
arrest cell proliferation and inhibit tumor growth in CRC cell lines and xenograft models 
expressing BRAFV600E, respectively.40 Based on this, a Phase II pilot study of vemurafenib 
was completed in patients with BRAFV600E metastatic CR using the maximum tolerated 
dose of 960 mg twice daily identified in melanoma studies.8 Of the 21 patients enrolled, a 
partial response was documented in one patient and seven patients were reported to have 
stable disease; however, the median PFS of 2.1 months did not suggest durable activity from 
single-agent BRAF inhibition. Similar to the rates seen in melanoma treatment, 15 of the 21 
(71%) patients experienced a grade 3 adverse event, including development of five 
squamous cell carcinomas of the skin, a known adverse event associated with single-agent 
BRAF inhibition.
Pharmacokinetic evaluations suggest that the discordant responses between the two diseases 
are due to marked differences in underlying tumor biology. In contrast to CRC, melanoma 
cells are not epithelial cells and do not typically express epidermal growth factor. The lack 
of response of BRAFV600E CRC to single-agent BRAF inhibition has been hypothesized to 
be due at least in part to feedback activation of EGFR resulting in MAPK signaling pathway 
reactivation.41,42 In vitro and in vivo models have shown decreased MAPK signaling and 
increased response with combined inhibition of BRAF and EGFR.40–42
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Based on this hypothesis, 15 patients with BRAFV600E metastatic CRC who had previously 
progressed on prior chemotherapy were enrolled to a pilot study of vemurafenib plus 
panitumumab, both at previously approved doses.43 Initial responses were encouraging, with 
some tumor regression seen in 10 of the 12 evaluable patients and less cutaneous toxicity 
than would be expected with either single agent.
In another attempt to inhibit signaling through the MAPK pathway, a single-arm study 
treated 43 patients with BRAFV600E metastatic CRC with the combination of dabrafenib and 
the MEK inhibitor trametinib.44 Responses were improved compared to single-agent BRAF 
inhibition, with 12% of patients achieving a partial response or better and 56% with stable 
disease. Of note, there was one complete response, with the duration of response of >36 
months, and 10 patients remained on study beyond 6 months. Adverse events were overall 
similar to what has been seen with combined BRAF and MEK inhibition in melanoma, 
notably with pyrexia occurring in 30% of patients and being the most common cause of 
treatment delay and dose reductions.
These approaches to MAPK signaling inhibition were combined in a Phase I/II clinical trial, 
which enrolled patients with BRAFV600E CRC to the combination of dabrafenib, trametinib, 
and panitumumab.45 In the Phase I component, there were no dose-limiting toxicities and 
the most common adverse event was acneiform dermatitis. The Phase II expansion of this 
study then compared the dabrafenib, trametinib, and panitumumab triplet with doublets of 
either dabrafenib plus panitumumab or trametinib plus panitumumab. In the trametinib plus 
panitumumab arm, there were no confirmed responses, suggesting that inhibition of BRAF 
is necessary but not sufficient for response. The response rate to dabrafenib plus 
panitumumab arm was 10% (95% CI 1.2–31.7) compared to 21% (95% CI 12.5–43.3) for 
the triplet arm.46 For the 91 patients treated with triplet therapy, disease control (response 
plus stable disease rates) was achieved in 86% of patients, with a median duration of 
response of 7.6 months and a median PFS of 4.2 months.47 These results suggest a role for 
combined targeted therapies as a therapeutic option for BRAF mutant disease (Figure 1).
Activation of the PI3K/AKT pathway has also been shown in BRAFV600E CRC cell lines to 
mediate both innate and acquired resistances to BRAF inhibition.48 Preclinical work 
confirmed that combining blockade of PI3Kα, BRAF, and EGFR resulted in synergistic 
antiproliferative effects in vitro and tumor regression in xenograft models.49 This spurred a 
Phase Ib/II study evaluating the RAF inhibitor encorafenib in combination with cetuximab 
with or without the PI3Kα inhibitor alpelisib in BRAFV600E metastatic CRC.50 Although 
high rates of grade III/IV adverse effects of 69% in the two-drug arm and 79% in the three-
drug arm were reported, the maximum tolerated dose was not reached in either arm.50 The 
overall response rates in the 54 patients treated were 19 and 18% in the two-and three-drug 
arms, with a median PFS of 3.7 and 4.2 months, respectively.50 Of note, this was a heavily 
pretreated population with the majority of patients having received two or more prior lines 
of therapy and >25% having received prior anti-EGFR therapy.
Concurrently with the development of targeted therapies, a Phase 1b study evaluated the 
combination of targeted therapies in combination with chemotherapy with a three-drug 
regimen of vemurafenib, cetuximab, and irinotecan.51 The combination was well tolerated 
Ursem et al. Page 7
Gastrointest Cancer. Author manuscript; available in PMC 2018 April 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
with the most common adverse effects being fatigue, diarrhea, nausea, and rash, and 
responses were seen in 35% of evaluable patients. This led to the Phase II Southwest 
Oncology Group (SWOG) 1406 trial, the first-ever randomized controlled trial in 
BRAFV600E-mutant metastatic CRC, evaluating irinotecan plus cetuximab with or without 
vemurafenib.52 The primary endpoint was PFS, and cross-over to the experimental arm with 
vemurafenib was allowed. With heightened awareness and increased testing for BRAFV600E 
among local oncology providers, accrual to SWOG 1406 was swifter than projected; 106 
patients enrolled in <1.5 years. Reflecting the insight of the investigators’ awareness of the 
unique challenges of measuring peritoneal metastasis and ascites in this patient population, 
SWOG 1406 included patients with nonmeasurable disease according to the RECIST 1.1 
criteria. SWOG 1406 reported a median PFS of 4.4 vs 2.0 months for the three-drug regimen 
(irinotecan, cetuximab, and vemurafenib) vs the two-drug regimen (irinotecan and 
cetuximab) (HR 0.42; 95% CI 0.26–0.55; P<0.001). Response rates in this study were 16 vs 
4%, respectively (P=0.09). Of note, neutropenia, anemia, and nausea occurred more 
frequently in the arm that included vemurafenib; however, the proportions of patients who 
developed rash and fatigue were comparable.
Correlative laboratory studies performed in conjunction with these studies provide a 
sobering reminder of how little we know. A study of molecular alterations in paired 
exposure biopsies obtained before and after exposure to BRAF inhibition showed acquisition 
of KRAS amplification, BRAF amplification, and MEK1 mutation following exposure to 
BRAF inhibitors.53 Similarly, analysis of circulating tumor DNA revealed the emergence of 
RAS mutations at disease progression in nearly half of patients following treatment with 
dabrafenib, trametinib, and panitumumab.47 Each of these alterations results in reactivation 
of the MAPK pathway, and these findings point to the critical importance of signaling 
through this pathway for the growth of BRAFV600E-mutant CRC cells. Additionally, 
analysis of pERK suppression from tumor samples after treatment with the combination of 
dabrafenib, trametinib, and panitumumab showed less suppression than what is seen with 
treatment with dabrafenib alone in melanoma, suggesting that we are currently still unable to 
inactivate MAPK pathway signaling in BRAFV600E-mutant CRC. This pathway dependence 
intimates that ongoing efforts to inhibit MAPK signaling may be necessary to achieve 
improvements in clinical response.
The intersection of BRAF and MSI
As noted earlier, there is a significant overlap between BRAFV600E and sporadic high-level 
MSI in CRC. In previously completed randomized trials, 16–33% of MSI-high tumors also 
harbored BRAFV600E mutations.44,46,50 In a population-based cohort of 1,253 patients, 52% 
of the 193 MSI-high cases were also BRAF mutant, while 55% of the BRAF mutant cases 
were also MSI-high.26 In this population, MSI-high status was associated with significantly 
lower CRC-specific mortality (multivariable HR =0.28, 95% CI 0.17–0.46; P<0.001) and the 
presence of a BRAFV600E mutation was associated with significantly higher CRC-specific 
mortality (multivariable HR =1.64, 95% CI 1.18–2.27; P=0.003), as seen in other studies. 
Within each subgroup, MSI and BRAFV600E status remained prognostic, such that 
BRAFV600E was associated with higher mortality in both MSS and MSI-high patients, and 
MSI-high tumors were associated with decreased mortality in both BRAF-wild-type and -
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mutated patients.26 These results suggest that the presence of a BRAFV600E mutation may 
diminish the more favorable prognosis afforded by MSI-high status in metastatic CRC.
However, it is not clear that this relationship holds true for stage III CRC, where studies have 
had conflicting results. A study performed on tumor specimens from the Intergroup 0135 
trial for stage III CRC found that MSI-high and BRAF-wild-type patients had the best long-
term survival but found no differences between MSI-high/BRAFV600E-mutant, MSS/
BRAFV600E-mutant, and MSS/BRAF-wild-type patients.54 A similar analysis performed on 
specimens from the adjuvant CALGB 89803 trial also showed that MSI-high and BRAF-
wild-type tumors are associated with the best prognosis but identified MSI/BRAFV600E-
mutant and MSS/BRAF-wild-type patients to have an intermediate prognoses, while MSS/
BRAFV600E-mutant patients have the worst prognosis.55 This finding parallels findings from 
patients with metastatic CRC.
The recent US Food and Drug Administration (FDA) approvals of two checkpoint inhibitors, 
pembrolizumab and nivolumab, for the treatment of MSI-high metastatic CRC transformed 
the therapeutic landscape for the small subset of metastatic CRC patients with MSI-high 
tumors (~4%). Given the substantial overlap between MSI-high status and BRAF mutation, 
there is a considerable interest in the application of checkpoint inhibitors in the subset of 
patients with MSI-high BRAFV600E CRC.
Pembrolizumab is a monoclonal antibody against the programed death receptor 1 (PD-1), 
which has been shown to increase immune recognition of tumor across a variety of tumor 
types. In a Phase II study of pembrolizumab given to 10 MSI-high and 18 MSS metastatic 
CRC patients, the response rates were 40 and 0%, respectively.56 This led to an expansion 
cohort for a total of 28 MSI-high patients, in whom the response rate was 50% (95% CI 31–
69%).57 Median PFS had not been reached at the time of presentation at the 2016 ASCO 
Annual Meeting. However, there were no identified patients with BRAF mutations in this 
cohort; thus, it is not yet clear from this study if presence of a BRAFV600E was associated 
with the likelihood of response.
Nivolumab, the second checkpoint inhibitor to be FDA approved for MSI-high metastatic 
CRC, is also a monoclonal antibody directed against PD-1. The Phase II Checkmate-142 
study reported a 31% (95% CI 20.8–42.9) response rate and a 69% (95% CI 57–79) disease 
control rate in 74 MSI-high metastatic CRC patients treated with nivolumab.58 Similar to 
what has been seen in other studies of checkpoint blockade, responses were often durable 
and median PFS has not yet been reported. Of the 16% of patients with a BRAF mutation 
(n=12), an objective response was seen in 25%. Although this response rate is similar to 
what has thus far been observed with the aforementioned targeted BRAF inhibition 
combinations, the possibility of durable disease control may be much higher with checkpoint 
inhibition; this remains an area of active investigation.
The role for metastectomy
Finally, our review would not be completely without mention of the management of 
oligometastatic disease. Distinct from other cancer types, CRC is one of the rare solid 
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tumors where cure is feasible in the presence of limited metastatic disease.59 However, 
careful selection for metastasectomy is widely acknowledged as a predictor for the benefit of 
surgical intervention. Relevant to this discussion is whether the detection of BRAFV600E 
mutation should deter providers from pursuing metastectomy.
In a single-center retrospective study of 92 patients, the presence of BRAFV600E was 
associated with less frequent presentations of liver-limited disease (41 vs 63%; P<0.01) and, 
not surprisingly, fewer patients with a BRAFV600E mutation were candidates for 
metastectomy (41 vs 26%; P<0.01).20 Among those patients with BRAFV600E tumors who 
underwent metastectomy, a trend toward shorter recurrence-free survival after metastectomy 
(7 vs 11 months, P=0.084) and a significantly shorter OS (2-year OS 61 vs 86%; P=0.003) 
were reported. Additionally, of the 20 patients with BRAFV600E mutations who underwent 
resection with curative intent (15 for liver metastases, four for lung metastases, and one for 
ovarian metastasis), 18 (90%) patients developed recurrence.
Given the high risk of recurrence after metastectomy in this population, along with the 
potential morbidity of surgery, we recommend metastectomy only in very carefully selected 
patients who have truly liver-limited disease and have previously achieved durable disease 
control in response to systemic therapy.
Future directions
Reflecting the rapid evolution of efforts for this small subset of CRC patients, the first-ever 
Phase III study is now underway evaluating the combination of BRAF, EGFR, and MEK 
inhibition (Figure 2).46 The Phase III BEACON CRC study is currently enrolling patients 
with BRAFV600E metastatic CRC to evaluate the combination of encorafenib, cetuximab, 
and the MEK inhibitor binimetinib.60 In the initial safety lead-in, 30 patients received triplet 
therapy with good tolerability and a confirmed overall response rate of 41%.61 Additionally, 
there is suggestion of a possibly more durable response than has previously been seen with 
BRAF inhibition, with 76% of patients remaining on study at a median of 5.6 months of 
treatment. The Phase III component is currently enrolling to the three arms of encorafenib 
plus cetuximab vs encorafenib, cetuximab and binimetinib vs FOLFIRI, or irinotecan plus 
cetuximab (at the discretion of the investigator) (NCT02928224). BEACON will potentially 
serve as a licensing trial for BRAF-inhibitor-based combination therapy for metastatic CRC 
but is not projected to reach its accrual goal until 2019.
Further efforts to elucidate other mechanisms of resistance to BRAF inhibition are an area of 
active investigation. As an example, researchers have identified increased Wnt pathway 
signaling as potentially cooperating with signaling through the MAPK pathway to sustain 
BRAFV600E tumor growth. We are currently awaiting results of NCT02278133, which has 
completed the enrollment of patients with both BRAFV600E and Wnt pathway mutations 
who were treated with the Wnt inhibitor WNT974 in combination with encorafenib and 
cetuximab.62
Finally, clinical trials combining therapies targeting the MAPK pathway with 
immunotherapy are in development.
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Summary of recommendations for clinical practice
Acknowledging that most data guiding the management of patients with metastatic 
BRAFV600E CRC are based upon small sample sizes and that the management of this 
condition is dynamic, the following clinical recommendations represent a compilation from 
the currently available data, existing clinical practice guidelines, as well as our own clinical 
experiences.
• Current NCCN guidelines recommend genomic testing to specifically include 
BRAF testing at the time of diagnosis of metastatic CRC.31 The testing can be 
done either on the primary tumor or on tissue from a metastatic site, as the 
results for this gene have been shown to be highly concordant.63 With improved 
recognition of poor prognosis and distinct clinical features of this population, 
earlier identification of a BRAFV600E mutation may expand therapeutic and/or 
clinical trial options before a patient faces clinical deterioration.
• For fit patients with a de novo presentation of metastatic CRC with BRAFV600E 
mutation for whom a clinical trial is not immediately available, we recommend 
considering FOLFOXIRI plus bevacizumab as first-line therapy in effort to 
obtain disease control.
• The likelihood of response from anti-EGFR monotherapies is low, and we 
recommend against the use of anti-EGFR therapy in patients with a known 
BRAFV600E tumor31 outside of the context of a clinical trial, particularly for 
those with right-sided primary tumors.
• For MSI-high tumors harboring a BRAFV600E mutation, we recommend 
treatment with a checkpoint inhibitor treatment prior to considering BRAF-
targeted therapy due to the higher potential for durable disease control; however, 
we acknowledge that checkpoint inhibitors and targeted therapies have not been 
studied in a head-to-head comparison.
• For MSS tumors harboring a BRAFV600E mutation or for patients with MSI-high 
BRAFV600E-mutated tumors who have previously progressed on a checkpoint 
inhibitor, we recommend enrollment on a clinical trial when feasible. However, 
we acknowledge that access to a tertiary medical center is not available to all 
patients.
• Pending results of the ongoing Phase III BEACON trial, the sum of data to date 
support the hypothesis that while targeted agents appear to be inactive as 
monotherapies in BRAFV600E-mutant CRC, combinations of BRAF, MEK, and 
other pathway inhibitors may have at least temporary efficacy. Access to these 
medications is currently not FDA approved for the treatment of metastatic 
BRAFV600E CRC; however, off-label use of these combinations merits 
consideration and is substantiated by a growing body of literature. In view of 
this, January 2018 updates to the NCCN Colorectal Guidelines included new 
recommendations regarding the treatment of these patients and off-label usage is 
likely to be more readily available. Currently, our preferred combinations include 
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dabrafenib, trametinib, and panitumumab,41 or vemurafenib, cetuximab, and 
irinotecan,47 with selection based upon toxicity profiles.
• In highly selected patients with very limited liver-only metastasis(es), curative 
intent metastectomy can be considered. However, patients should be counseled 
extensively on the high risk of recurrence following any surgical intervention.
Conclusion
The personalization of cancer care is rooted in the premise that there are subsets of patients 
with tumors harboring clinically relevant targets for patient-specific treatments. CRC is 
historically a disease that has been notable for its dearth of biomarkers that are predictive of 
response to targeted therapies. In a rapidly evolving era of personalized oncology, CRC has 
been eclipsed by other tumor types, with very little of the abundant genomic data bearing 
any relevance for clinical decision-making. BRAFV600E-mutated CRC is an exception, 
however, and considerable progress has been made in recent years to enhance both our 
understanding of the biology of BRAFV600E-mutant metastatic CRC and the associated 
therapeutic landscape.
While the overall prognosis for BRAFV600E mutant metastatic CRC is still far worse than 
for BRAF-wild-type CRC, the incremental progress thus far should be credited to the 
consistent incorporation of robust, high-quality correlative science into the clinical trials of 
BRAF inhibition and rapid translation of laboratory discovery into clinical trial design. Still, 
despite multiple studies showing evidence of response to combined BRAF/EGFR and 
BRAF/MEK inhibition, reported overall response rates and median PFS are modest at best, 
providing a sobering reminder of the ongoing need for therapeutic development for this 
disease. Looking ahead, we remain optimistic that ongoing efforts to impede signaling 
through the MAPK pathway through alternate targets will result in longer and more durable 
clinical responses for this unique subset of patients.
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Figure 1. 
Targeted therapy approaches in clinical trials for BRAFV600E mutant CRC.
Abbreviation: CRC, colorectal cancer.
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Figure 2. 
Schematic representation of the Phase III study of encorafenib + cetuximab plus or minus 
binimetinib vs irinotecan/cetuximab or infusional 5-FU/FA/irinotecan (FOLFIRI)/cetuximab 
with a safety lead-in of encorafenib + binimetinib + cetuximab in patients with BRAFV600E-
mutant metastatic CRC (BEACON CRC).
Abbreviations: CRC, colorectal cancer; FA, folinic acid; 5-FU, 5-fluorouracil; FOLFIRI, 5-
fluorouracil, leucovorin and irinotecan.
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